Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
McKinsey
Express Scripts
Johnson and Johnson

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ARN-509

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug ARN-509?

ARN-509 is an investigational drug.

There have been 37 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2020.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Janssen Scientific Affairs, LLC, Aragon Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are forty US patents protecting this investigational drug and four hundred and fifty-nine international patents.

Recent Clinical Trials for ARN-509
TitleSponsorPhase
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate CancerNational Cancer Institute (NCI)Phase 3
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate CancerNRG OncologyPhase 3
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)Janssen Research & Development, LLCPhase 4

See all ARN-509 clinical trials

Clinical Trial Summary for ARN-509

Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509

See all ARN-509 clinical trials

US Patents for ARN-509

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ARN-509   Start Trial Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
ARN-509   Start Trial Androgen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
ARN-509   Start Trial Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
ARN-509   Start Trial Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
ARN-509   Start Trial System and method for diagnosis and treatment Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)   Start Trial
ARN-509   Start Trial Compositions and methods for treatment of prostate carcinoma PELLFICURE PHARMACEUTICALS, INC. (La Jolla, CA)   Start Trial
ARN-509   Start Trial System and method for diagnosis and treatment Pop Test Oncology Limited Liability Company (Cliffside Park, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ARN-509

Drugname Country Document Number Estimated Expiration Related US Patent
ARN-509 Argentina 107432 2036-01-11   Start Trial
ARN-509 Australia 2017207268 2036-01-11   Start Trial
ARN-509 Australia 2019203280 2036-01-11   Start Trial
ARN-509 Brazil 112018014015 2036-01-11   Start Trial
ARN-509 Canada 3010509 2036-01-11   Start Trial
ARN-509 China 108473471 2036-01-11   Start Trial
ARN-509 Colombia 2018007738 2036-01-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Express Scripts
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.